These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 10522891)

  • 1. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups.
    Gorter JW
    Neurology; 1999 Oct; 53(6):1319-27. PubMed ID: 10522891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group.
    Ann Neurol; 1997 Dec; 42(6):857-65. PubMed ID: 9403477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage.
    ESPRIT
    Stroke; 2003 Jun; 34(6):e45-6. PubMed ID: 12730559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting Major Bleeding in Ischemic Stroke Patients With Atrial Fibrillation.
    Hilkens NA; Algra A; Greving JP
    Stroke; 2017 Nov; 48(11):3142-3144. PubMed ID: 28931618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia.
    European Atrial Fibrillation Trial Study Group
    N Engl J Med; 1995 Jul; 333(1):5-10. PubMed ID: 7776995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
    Arch Intern Med; 1996 Feb; 156(4):409-16. PubMed ID: 8607726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral anticoagulation for cerebral ischemia of arterial origin: high initial bleeding risk.
    Torn M; Algra A; Rosendaal FR
    Neurology; 2001 Dec; 57(11):1993-9. PubMed ID: 11739815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
    Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
    Lancet; 1993 Nov; 342(8882):1255-62. PubMed ID: 7901582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.
    Lip GY; Frison L; Halperin JL; Lane DA
    J Am Coll Cardiol; 2011 Jan; 57(2):173-80. PubMed ID: 21111555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study.
    Chan EW; Lau WC; Siu CW; Lip GY; Leung WK; Anand S; Man KK; Wong IC
    Heart Rhythm; 2016 Aug; 13(8):1581-8. PubMed ID: 27033342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
    Rost NS; Giugliano RP; Ruff CT; Murphy SA; Crompton AE; Norden AD; Silverman S; Singhal AB; Nicolau JC; SomaRaju B; Mercuri MF; Antman EM; Braunwald E;
    Stroke; 2016 Aug; 47(8):2075-82. PubMed ID: 27387994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin.
    Algra A; de Schryver EL; van Gijn J; Kappelle LJ; Koudstaal PJ
    Cochrane Database Syst Rev; 2001; (4):CD001342. PubMed ID: 11687110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with nonrheumatic atrial fibrillation. European Atrial Fibrillation Trial (EAFT) Study Group.
    van Latum JC; Koudstaal PJ; Venables GS; van Gijn J; Kappelle LJ; Algra A
    Stroke; 1995 May; 26(5):801-6. PubMed ID: 7740570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shifting Perceptions of Risk and Reward: Use of Anticoagulation in Patients With Acute Brain Ischemia and Atrial Fibrillation: Nine-Year Data From a National Acute Stroke Registry (National Acute Stroke Israeli Survey [NASIS]).
    Schwammenthal Y; Tsabari R; Orion D; Merzlyak O; Haratz S; Peretz S; Bornstein NM; Ifergane G; Einhorn M; Schwammenthal E; Geva D; Tanne D;
    Stroke; 2017 Apr; 48(4):1092-1094. PubMed ID: 28258255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
    Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
    J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation.
    Hylek EM; Skates SJ; Sheehan MA; Singer DE
    N Engl J Med; 1996 Aug; 335(8):540-6. PubMed ID: 8678931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percutaneous left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation and contraindication for anticoagulation.
    Grosset-Janin D; Barth E; Bertrand B; Detante O
    Rev Neurol (Paris); 2015 May; 171(5):426-32. PubMed ID: 25912470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.